Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 4

Validity and reliability of the Turkish version of the Michigan Neuropathy Screening Instrument

Pages
789–797
Publication Date
2020-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It must be obtained a minimum of 4 points from the questionnaire part and a minimum of 2.5 points from the physical assessment part for the diagnosis of neuropathy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: The aim of this study was to demonstrate the validity and reliability of the Turkish version of the Michigan Neuropathy Screening Instrument MNSI-TR .
📊
Key Findings & Data:Materials and methods: The study included 127 patients aged 45-76 years who were previously diagnosed with type 1 or 2 diabetes.
💡
Conclusion & Impact:It must be obtained a minimum of 4 points from the questionnaire part and a minimum of 2.5 points from the physical assessment part for the diagnosis of neuropathy
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Michigan · diabetic neuropathy · diabetes mellitus

Abstract

Background/aim: The aim of this study was to demonstrate the validity and reliability of the Turkish version of the Michigan Neuropathy Screening Instrument MNSI-TR . Materials and methods: The study included 127 patients aged 45-76 years who were previously diagnosed with type 1 or 2 diabetes. Stability of the instrument was assessed by intraclass correlation coefficient. Reliability of the MNSI-TR was assessed using the Kuder- Richardson formula 20 test, item-total correlations, and floor/ceiling effect. Validity was evaluated with receiver operating characteristic curve analysis. A logistic regression model was used to determine to what degree the MNSI-TR explain nerve conduction study NCS results in the prediction of neuropathy. Results: With a cut-off value of 3.5 for the questionnaire, sensitivity and specificity of the MNSI-TR were 75.5% and 68.1%, respectively. A cut-off of 2.75 for the physical assessment part of the scale resulted in 87.5% sensitivity and 93.6% specificity. The scale was able to diagnose neuropathy in the rate of 71.5% of the patients diagnosed with neuropathy by NCS. Conclusion: The MNSI-TR is a valid and reliable method for evaluating diabetic peripheral neuropathy in Turkish speaking societies. It must be obtained a minimum of 4 points from the questionnaire part and a minimum of 2.5 points from the physical assessment part for the diagnosis of neuropathy

🔖

Cite This Article

REYHANİOĞLU, D. A., ADIYAMAN, S. C., BEKTAŞ, M., BULUT, O., SAYDAM, B. Ö., BAYRAKTAR, F., KARA, B. (2020). Validity and reliability of the Turkish version of the Michigan Neuropathy Screening Instrument. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 4, 789–797. https://ajindex.com/articles/113163

References (1)

  1. Chaudhury A, Duvoor C, Dendi R, Sena V, Kraleti S et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Frontiers in Endocrinology 2017; 8 (6). doi: 10.3389/fendo.2017.00006 2. Çakici N, Fakkel TM, Van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabetic Medicine 2016; 33 (11): 1466-1476. doi: 10.1111/dme.13083 3. Qureshi MS, Iqbal M, Zahoor S, Ali J, Javed MU. Ambulatory screening of diabetic neuropathy and predictors of its severity in outpatient settings. Journal of endocrinological investigation. 2016; 40 (4): 425-430. doi: 10.1007/s40618-016- 0581-y 4. Hershey DS. Diabetic Peripheral Neuropathy: Evaluation and Management. The journal for nurse practitioners:JNP 2017; 13 (3): 199-204. doi: 10.1016/j.nurpra.2016.08.034 5. Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneapolis, Minn.) 2014; 20 (5): 1226. doi: 10.1212/01.CON.0000455884.29545.d2 6. Yang Z, Chen R, Zhang Y, Huang Y, Hong T et al. Scoring systems to screen for diabetic peripheral neuropathy. The Cochrane database of systematic reviews. 2014; 3. doi: 10.1002/14651858.CD010974.pub2 7. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/metabolism research and reviews. 2011; 27 (7): 629-638. doi: 10.1002/dmrr.1225 8. Smith AG. Do all neuropathy patients need an EMG at least once?. Continuum (Minneapolis, Minn.) 2014; 20 (5): 1430- 1434. doi: 10.1212/01.CON.0000455870.45685.c7. 9. Theriault M, Dort J, Sutherland G, Zochodne DW. A prospective quantitative study of sensory deficits after whole sural nerve biopsies in diabetic and nondiabetic patients. Surgical approach and the role of collateral sprouting. Neurology 1998; 50 (2): 480-484. doi:10.1212/wnl.50.2.480 10. Kennedy WR, Nolano M, Wendelschafer-Crabb G, Johnson TL, Tamura E. A skin blister method to study epidermal nerves in peripheral nerve disease. Muscle & Nerve 1999; 22 (3): 360- 371. doi: 10.1002/(SICI)1097-4598(199903)22:33.0.CO;2-J 11. Kennedy WR, Wendelschafer-Crabb G, T. Johnson. Quantitation of epidermal nerves in diabetic neuropathy. Neurology 1996; 47 (4): 1042-1048. doi: 10.1212/wnl.47.4.1042 12. Dahlin LB, Eriksson KF, Sundkvist G. Persistent postoperative complaints after whole sural nerve biopsies in diabetic and non-diabetic subjects. Diabetic Medicine 1997; 14 (5): 353- 356. doi